PRTA
Prothena Corporation plc

1,993
Mkt Cap
$482.85M
Volume
7.00
52W High
$16.16
52W Low
$4.32
PE Ratio
-1.98
PRTA Fundamentals
Price
$8.97
Prev Close
$9.07
Open
$9.03
50D MA
$9.28
Beta
1.05
Avg. Volume
509,965.50
EPS (Annual)
-$4.53
P/B
1.72
Rev/Employee
$59,411.04
$214.91
Loading...
Loading...
News
all
press releases
FY2026 EPS Estimates for Prothena Boosted by HC Wainwright
Prothena Corporation plc (NASDAQ:PRTA - Free Report) - Investment analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of Prothena in a report released on Friday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Prothena (NASDAQ:PRTA) Price Target Raised to $12.00
Royal Bank Of Canada lifted their target price on shares of Prothena from $11.00 to $12.00 and gave the stock a "sector perform" rating in a report on Friday...
MarketBeat·5d ago
News Placeholder
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
PRTA posts a narrower year-over-year Q4 loss. Revenues miss estimates, as it outlines 2026 cash burn guidance and eyes key milestones from partners.
Zacks·5d ago
News Placeholder
Prothena Q4 Earnings Call Highlights
Prothena (NASDAQ:PRTA) used its fourth-quarter and full-year 2025 results call to highlight partner-driven clinical momentum, updates from its wholly owned preclinical portfolio, and a sharper cash...
MarketBeat·6d ago
News Placeholder
Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of +1.12% and -99.30%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Prothena (NASDAQ:PRTA) Announces Earnings Results
Prothena (NASDAQ:PRTA - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts...
MarketBeat·6d ago
News Placeholder
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported...
Business Wire·6d ago
News Placeholder
Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?
PRTA stock declines 36.8% in a year as birtamimab's failure, earnings miss and reliance on partner programs weigh on investor confidence.
Zacks·9d ago
News Placeholder
FTRE vs. PRTA: Which Stock Is the Better Value Option?
FTRE vs. PRTA: Which Stock Is the Better Value Option?
Zacks·12d ago
News Placeholder
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
Business Wire·13d ago
<
1
2
...
>

Latest PRTA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.